Law Offices of Thomas J. Lamb

  • About Firm
  • Practice Areas
  • Free Case Evaluation
  • Quick Contact Form
  • Frequently Asked Questions
  • Attorney Tom Lamb

The presence of pleural effusion is an independent prognostic factor in patients with malignant pleural mesothelioma

January 7, 2025 By Law Offices of Thomas J. Lamb, P.A.

Abstract:  Malignant pleural mesothelioma (MPM) is a rare form of thoracic malignancy with a poor prognosis. Pleural effusion (PE) occurs in the majority of patients with MPM; however, its impact on MPM outcomes remains controversial. We searched for eligible patients from the Surveillance, Epidemiology, and End Results (SEER) database, and clinicopathological information and outcomes were collected. Cox proportional hazard regression analyses were utilized to evaluate the association of [pleural effusion (PE)] and other factors with overall survival (OS) and cancer-specific survival (CSS) in patients with MPM. A total of 4185 patients were extracted from the SEER database from 2000 to 2021. The median age of the cohort was 73 years, with a predominance of male patients and epithelioid MPM as the main histological subtype. Univariate Cox regression revealed associations between [pleural effusion (PE)], age, sex, marital status, histology, stage, and treatment with both OS and CSS. Besides, multivariate analyses indicated that PE was independently associated with poorer OS and CSS in patients with MPM, regardless of age, sex, histology, stage, and treatment. Subgroup analyses suggested that PE has a remarkable impact on patients undergoing surgery. [Pleural effusion (PE)] might serve as an independent prognostic factor in patients with MPM, especially in surgery recipients. Consequently, the development of pleural effusion in these patients should receive increased attention. Future studies are needed to validate these findings, particularly concerning the effect of [pleural effusion (PE)] in other clinical settings, such as immunotherapy.

Introduction:  Malignant mesothelioma is a rare malignancy originating from mesothelial cells, with malignant pleural mesothelioma (MPM) being the main form. It is confirmed that some occupational exposures, such as asbestos and erionite, play critical roles in the development of MPM. Additionally, iatrogenic exposure to radiotherapy could also increase the risk of developing second malignancies, including malignant mesothelioma. The latest epidemiological data from World Health Organization (WHO) revealed that approximately 30,000 new cases and new deaths of mesothelioma occurred globally each year, accounting for 0.2% and 0.3% of all malignancies, respectively. Although not common in clinical settings, the disease burden of MPM should not be underestimated due to the lack of curative treatment and poor prognosis, of which the median survival is less than 2 years, with a low 5-year survival rate. MPM is mainly classified into three histological subtypes: epithelial, biphasic, and sarcomatoid. Among them, the epithelioid subtype is associated with better prognosis, whereas patients with sarcomatoid histology had the worst outcomes, with a median survival of only 4 months. Meanwhile, MPM is often accompanied by pleural effusion (PE) on initial diagnosis or during disease development, and it is proved that the presence of [pleural effusion (PE)] can lead to worse life quality10. However, limited evidence focused on the prognostic role of PE on MPM. This study aimed to explore the prognostic impact of [pleural effusion (PE)] in patients with MPM.  [Footnotes omitted] [Article continues at original source]


 Asbestos & Mesothelioma Information

  Asbestos-Mesothelioma Case Evaluation
Free.  Confidential.  No Obligation.

Filed Under: Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma diagnosis

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

DrugInjuryLaw.com

DrugInjuryWatch.com

Asbestos-Mesothelioma.com

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2025 · Law Offices of Thomas J. Lamb, P.A.